Webinar & Podcast Series
Enduring Internet Activities
7.0+ CME / CE Credits
From Cholesterol
to Dyslipidemia
Translating the 2026 Multi-Society Guidelines into Clinical Practice
Four monthly releases · August 2026 – December 2026
Month One available now
2.00 credits
Webinar 1.25 · Podcast 0.75
New month released on the last day of each month
8
CME / CE Activities
4
Monthly Releases
7.0+
CME / CE Credits
Enduring
Activity Type
Why this series
The guideline changed. Practice has to follow.
The 2026 Multi-Society Dyslipidemia Guidelines are broad and complex, and the gaps they expose are well documented: risk stratification, primary prevention, treatment goal attainment, non-statin utilization, and population-specific management. Understanding the recommendations is only the first step.
This series is built to close the distance between reading the guideline and applying it. Over four months, a CME/CE webinar and an expert-led podcast each month work through what changed, why it changed, and how it plays out across diverse patient populations and care settings.
The goal is competence and confidence at the point of care: better lipid control, fewer ASCVD events, and progress against the persistent disparities in cardiovascular care.
Target Audience
Clinicians involved in ASCVD risk assessment and lipid management.
Physicians
Pharmacists
Advanced Practice Providers
Dietitians
Cardiology
Endocrinology
Internal Medicine
Release Schedule
Four months, eight activities
Each month opens with one webinar and one podcast. Future months unlock on their release date.
Month 01
Understanding the New Dyslipidemia Paradigm
Available now
Month 02
Risk Assessment Reimagined
Releases 09.30.26
Month 03
Treatment Strategies and Targets
Releases 10.31.26
Month 04
Non-Statin Therapies and Emerging Treatments
Releases 11.30.26
Series Leadership
Series Co-Chairs
Dave L. Dixon
PharmD, FNLA, CLS
Series Co-Chair
Kaye-Eileen Willard
MD, FNLA
Series Co-Chair
What the series covers
Guideline updates emphasized throughout
1
Expanded focus beyond LDL-cholesterol to include remnant particles and Lp(a).
2
Earlier and lifetime risk assessment, with attention to cumulative lipid exposure.
3
Use of PREVENT risk equations instead of Pooled Cohort Equations.
4
Greater use of ApoB, Lp(a), and CAC scoring for risk refinement.
5
Reintroduction of treatment goals to guide therapy intensity and escalation.
6
Tailored management in special populations, including diabetes, CKD, women, older adults, and inherited lipid disorders.
Commercial Support
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation, Merck & Co., Inc., and Amgen Inc.
Month One is open
Understanding the New Dyslipidemia Paradigm. One webinar, one podcast, 2.00 CME/CE credits. Available through February 28, 2027.